Once prostate cancer becomes castration resistant, cancer cells may rapidly gain the ability to invade and to metastasize to lymph nodes and distant organs. The progression through hormone-dependent to hormone-independent/castration-resistant and metastatic PCa is poorly understood. In this review paper, we provide an overview on the cellular and molecular mechanisms underlying the process of tumor cell invasion and metastasis in prostate cancer. We specifically presented the most recent findings on the role of multiple cellular signaling pathways including androgen receptor (AR), mitogen-activated protein kinases (MAPK), Akt, transforming growth factor beta (TGF beta), interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) in t...
As the most frequently diagnosed cancer in North American men, prostate cancer can progress to the a...
Although castration-resistant prostate cancer (CRPC) as a whole, by its name, refers to the tumors t...
Prostate cancer is the second most common malignancy in males and the leading cause of cancer death....
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Prostate cancer (PCa) is initially driven by excessive androgen receptor (AR) signaling with androge...
Prostate cancer (PCa) is the most common malignancy affecting men in the western world. While radica...
textabstractProstate cancer has a high incidence in the western world. Early detection of the disea...
In spite of recent developments in diagnosis, staging and treatment, most patients with advanced pro...
Almost all patients who succumb to prostate cancer die of metastatic castration-resistant disease. A...
In spite of recent developments in diagnosis, staging and treatment, most patients with advanced pro...
In spite of recent developments in diagnosis, staging and treatment, most patients with advanced pro...
Prostate cancer is the most frequently diagnosed non-cutaneous malignancy and second leading cause o...
As the most frequently diagnosed cancer in North American men, prostate cancer can progress to the a...
Although castration-resistant prostate cancer (CRPC) as a whole, by its name, refers to the tumors t...
Prostate cancer is the second most common malignancy in males and the leading cause of cancer death....
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
This is an open-access article distributed under the terms of the Creative Commons Attribution Licen...
Prostate cancer (PCa) is initially driven by excessive androgen receptor (AR) signaling with androge...
Prostate cancer (PCa) is the most common malignancy affecting men in the western world. While radica...
textabstractProstate cancer has a high incidence in the western world. Early detection of the disea...
In spite of recent developments in diagnosis, staging and treatment, most patients with advanced pro...
Almost all patients who succumb to prostate cancer die of metastatic castration-resistant disease. A...
In spite of recent developments in diagnosis, staging and treatment, most patients with advanced pro...
In spite of recent developments in diagnosis, staging and treatment, most patients with advanced pro...
Prostate cancer is the most frequently diagnosed non-cutaneous malignancy and second leading cause o...
As the most frequently diagnosed cancer in North American men, prostate cancer can progress to the a...
Although castration-resistant prostate cancer (CRPC) as a whole, by its name, refers to the tumors t...
Prostate cancer is the second most common malignancy in males and the leading cause of cancer death....